Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "omidenepag" in Related Substance Name (exact match)

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

OMIDENEPAG

Z95F9F9LU4

Search for Structure

Status:

US Previously Marketed

Source:

OMLONTI by VISIOX PHARMA

(2022)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215092

First approved in 2022

Source:

OMLONTI by VISIOX PHARMA

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215092

Class (Stereo):

CHEMICAL (ACHIRAL)

PROSTAGLANDIN E2 RECEPTOR EP2 SUBTYPE

6GS8S5F0RP

Subunit 1 (358) Similarity Search

Sequence Search

Subunit 1 (358) Similarity Search

Status:

Other

Class:

PROTEIN

OMIDENEPAG ISOPROPYL

G0G0H52U6K

Search for Structure

Status:

US Previously Marketed

Source:

OMLONTI by VISIOX PHARMA

(2022)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215092

First approved in 2022

Source:

OMLONTI by VISIOX PHARMA

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215092

Class (Stereo):

CHEMICAL (ACHIRAL)

Structure of OMIDENEPAG

ACHIRAL

Protein

PROSTAGLANDIN E2 RECEPTOR EP2 SUBTYPE

Structure of OMIDENEPAG ISOPROPYL

ACHIRAL

OMIDENEPAG ISOPROPYL

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1